Statins and cognition: What can we learn from existing randomized trials?

CNS Spectrums

Volumn 10, Issue 11, 2005, Pages 867-874

  Xiong, Glen L ^a   Benson, Aaron ^a   Doraiswamy, P Murali ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ALZHEIMER DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

EID: 28944455358     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900019817     Document Type: Review

References (58)

1. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-880.
2. Sparks DL, Connor DJ, Browne PJ, et al. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002;6:324-331.
3. Colomb BA, Criqui MH, White H, Dimsdale JE. Conceptual foundations of the UCSD statin study. Arch Intern Med. 2004;164:153-162.
4. Austen B, Christodoulou G, Terry JE. Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging. 2002;6:377-382.
5. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139-1146.
6. Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase Alzheimer's disease AM 10. Proc Natl Acad Sci U S A. 2001;98:5815-5820.
7. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 1999;10:1699-1705.
8. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460-6464.
9. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
10. Sparks DL, Connor DJ, Browne PJ, et al. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002;6:324-331.
11. Sparks DL, Martin TA, Gross DR, Hunsaker JC. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech. 2000;52:287-290.
12. Sparks DL, Kuo YM, Roher A, et al. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Ann N Y Acad Sci. 2000;903:335-344.
13. Refolo LM, Pappollo MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890-899.
14. Park IH, Hwang EM, Hong HS, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging. 2003;24:637-643.
15. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346-350.
16. Hoglund K, Wiklund O, Vanderstichele H, et al. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 2004;61:333-337.
17. Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decreases the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Frontiers in Bioscience. 2002;7:50-59.
18. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
19. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phyenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophage. J Clin Invest. 1997;100:2671-2679.
20. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGCoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
21. Hebert P, Gaziano M, Chan K, Hennekens C. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278-313-321.
22. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
23. Wolorin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
24. Rockwood K, Kirkland S, Hogan D, et al. Use of lipid-lowering agents, indication bias, and risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
25. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;9:378-384.
26. Orsi A, Sherman O, Woldesellassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767-769
27. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003;23:726-730.
28. Breitner JC, Zandi PP, Li G, et al. Can statins prevent AD, or are they just prescribed less often to those with cognitive disorders? Abstract presented at: the Annual Meeting of the International Conference on Alzheimer's Disease and Related Disorders. July 17-22, 2004; Philadelphia, Penn.
29. Li G, Higdon R, Kukall WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63:1624-1628.
30. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217-224.
31. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol. 2005;62:1047-1051.
32. Doraiswamy PM, Steffens D, McQuoid D. Statin use and hippocampal volume in subjects at risk for Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2004;19:275-278.
33. Mason RP, Herbette LG, Silverman DI. Can altering serum cholesterol affect neurologic functions? J Mol Cell Caridiol. 1991;23:1339-1342.
34. Wardel J, Rogers P, Judd P, et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am J Med. 2000;108:547-553.
35. Zhang J, Muldoon MF, McKeown RE. Serum cholesterol concentrations are associated with visuomotor speed in men: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 2004;80:291-298.
36. Henderson VW, Guthrie JR, Dennerstein L. Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry. 2003;74:1530-1535.
37. Benton D. Do low cholesterol levels slow mental processing? Psychosom Med. 1995;57:50-53.
38. Botti RE, Triscari J, Pan HY, Zayat J. concentration of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol. 1991;14:256-261.
39. Serajuddin ATM, Ranadive SA, Mahoey EM. Relative lipophilicities, solubilities and structure-pharmacoligical consideration of 3-hydroxy- 3methylglutaryl-coenzyme A (reductase inhibitors pravastatin, lovastatin, mevastatin and simvastatin. J Pharm Sci. 1991;80:830-834.
40. Vgontzas AN, Kales A, Bixler EO, Manfreidi RL, Tyson KL. Effects of pravastatin and lovastatin on sleep efficiency and sleep states. Clin Pharmacol Ther. 1991;50:730-737.
41. Barth JD, Kruisbrink OA, Van Dijk AL. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolemia [letter]. Br Med J. 1990;301:669.
42. Schaefer EJ. HMG-CoA reductase inhibitors for hypercholesterolemia [letter]. N Engl J Med. 1988;19:1222.
43. Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15:426-432.
44. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989-996.
45. Gengo F, Cwudzinski D, Kindel P, et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18:209-214.
46. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of Lovastatin and pravastatin on cognitive function in military aircrew. Av Sp Env Med. 2001;72;805-812.
47. Botti RE, Triscari J, Pan HY, Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol. 1991;14:256-261.
48. Triscari J, Karkowitz JS, McGovern MW. Pravastatin and lovastatin in cerebrospinal fluid. Clin Neuropharmacol. 1993;16:559-560.
49. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clini Pharmacol. 1994;37:231-236.
50. Cutler N, Sramek J, Veroff A, et al. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clini Pharmacol. 1995;39:333-336.
51. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538-546
52. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individual: a randomized placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet. 2002;360:7-22.
53. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002(360)1623-1630.
54. Rise P, Colombo C, Galli C. Effects of simvastatin on the metabolism of polyunsaturated fatty acids on glycerolipid, cholesterol, and dev novo lipid synthesis in THP-1 cells. J Lipid Res. 1997;38:1299-1307.
55. Palomaki A, Malminiemi K, Metsa-Ketela T. Enhanced oxidizability of ubiquinol and tocopherol during lovastatin treatment. FEBS Letters. 1997;410:254-258.
56. Byington RP, Davis BR, Plehn FJ, et al. Reduction of stroke events with pravastatin: The prospective pravastatin pooling project. Circulation. 2001;103:387-392.
57. Sparks DL, Sabbgh M, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753-757
58. Sparks DL, Lopez J, Connor D. Sabbagh M, Seward J, Browne P. Alzheimer's Disease Cholesterol-Lowering Treatment Team. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT). J Mol Neurosci. 2003;20:407-410.